Brief: Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis
01/09/2026 21:40
BRIEF-Atyr Pharma Provides Update On Timing Of Regulatory Response For Planned Phase 3 Study Of Efzofitimod In Pulmonary Sarcoidosis Sept 1 (Reuters) - aTyr Pharma Inc ATYR.O:
ATYR PHARMA PROVIDES UPDATE ON TIMING OF REGULATORY RESPONSE FOR PLANNED PHASE 3 STUDY OF EFZOFITIMOD IN PULMONARY SARCOIDOSIS
ATYR PHARMA - EXPECTS FDA RESPONSE BY MID-SEPTEMBER 2026 FOR PHASE 3 EFZOFITIMOD STUDY
Source text: ID:nGNX6hDdPQ
Further company coverage: ATYR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on aTyr Pharma
See all newsBrief: Atyr Pharma Announces Research Collaboration With Montefiore Einstein
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry
aTyr rises as FDA aligns on late-stage lung disease study plan